Dr. Steven G. DuBois, MD, MS
Claim this profileDana-Farber Cancer Institute
Area of expertise
Cancer
Steven G. DuBois, MD, MS has run 7 trials for Cancer. Some of their research focus areas include:
Solid Tumors
Steven G. DuBois, MD, MS has run 7 trials for Solid Tumors. Some of their research focus areas include:
Affiliated Hospitals
Dana Farber Cancer Institute
Boston Children's Hospital
Clinical Trials Steven G. DuBois, MD, MS is currently running
CBL0137
for Cancer
This trial tests CBL0137, a drug that blocks signals inside cancer cells, in patients whose solid tumors, including CNS tumors or lymphoma, have returned or not responded to treatment. By interfering with the cells' internal communication, the drug aims to stop their growth and cause them to die. CBL0137, also known as Curaxin, has shown antitumor activity in multiple cancers, including glioblastoma, renal cell carcinoma, melanoma, neuroblastoma, and small cell lung cancer.
Recruiting
1 award
Phase 1 & 2
13 criteria
Repotrectinib
for Solid Tumors in Young Patients
Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic lymphoma kinase (ALK), receptor tyrosine kinase encoded by the gene ROS1 (ROS1), or neurotrophic receptor kinase genes encoding TRK kinase family (NTRK1-3) alterations to estimate the Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) and select the Pediatric Recommended Phase 2 Dose (RP2D). Phase 2 will determine the anti-tumor activity of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring ROS1 or NTRK1-3 alterations.
Recruiting
1 award
Phase 1 & 2
14 criteria
More about Steven G. DuBois, MD, MS
Clinical Trial Related
3 years of experience running clinical trials · Led 13 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Steven G. DuBois, MD, MS has experience with
- Topotecan
- Cyclophosphamide
- Temozolomide
- Seclidemstat
- Cabozantinib
- Myeloid Growth Factor
Breakdown of trials Steven G. DuBois, MD, MS has run
Solid Tumors
Ewing Sarcoma
Soft Tissue Sarcoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Steven G. DuBois, MD, MS specialize in?
Steven G. DuBois, MD, MS focuses on Cancer and Solid Tumors. In particular, much of their work with Cancer has involved Stage IV patients, or patients who are RET positive.
Is Steven G. DuBois, MD, MS currently recruiting for clinical trials?
Yes, Steven G. DuBois, MD, MS is currently recruiting for 3 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Steven G. DuBois, MD, MS has studied deeply?
Yes, Steven G. DuBois, MD, MS has studied treatments such as Topotecan, Cyclophosphamide, Temozolomide.
What is the best way to schedule an appointment with Steven G. DuBois, MD, MS?
Apply for one of the trials that Steven G. DuBois, MD, MS is conducting.
What is the office address of Steven G. DuBois, MD, MS?
The office of Steven G. DuBois, MD, MS is located at: Dana-Farber Cancer Institute, Boston, Massachusetts 02215 United States. This is the address for their practice at the Dana-Farber Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.